

Invitation to Participate in a Multicentre Study

Tolerability and Disease Activity Outcomes with Incretin-Based Therapies in Inflammatory Bowel Disease: a multicentre retrospective comparative cohort study

24 March 2026

Dear Colleagues,

Following approval by the ECCO Governing Board, I would like to invite interested centres within the ECCO network to participate in the study entitled “Tolerability and Disease Activity Outcomes with Incretin-Based Therapies in Inflammatory Bowel Disease: a multicentre retrospective comparative cohort study”.

This investigator-initiated project aims to generate robust real-world evidence on the tolerability and clinical impact of incretin-based therapies in inflammatory bowel disease. The study will evaluate serious gastrointestinal adverse events, treatment-limiting intolerance, and changes in IBD activity over 12 months in adult patients with Crohn’s disease, ulcerative colitis, or IBD-unclassified who initiated a GLP-1 receptor agonist or tirzepatide between 1 January 2020 and 31 December 2025. Participating centres will also contribute a contemporaneous comparator cohort of IBD patients with diabetes and/or obesity initiating non-incretin therapy, in accordance with the approved protocol.

Centres willing to participate should be able to identify eligible patients retrospectively from local clinical records or IBD databases. The full protocol, eCRF, and completion guidance will be provided centrally by the Principal Investigator.

This collaboration is intended to provide clinically relevant data to support counselling, monitoring, and risk stratification when incretin-based therapies are prescribed to IBD patients in routine practice. Authorship and acknowledgements for future scientific outputs will follow documented contribution and predefined study criteria.

Centres interested in joining the project are invited to contact me by email, indicating the participating centre and the local investigator.

Contact details

Davide Giuseppe Ribaldone
Principal Investigator
Gastroenterology Unit, Department of Medical Sciences, University of Turin
Città della Salute e della Scienza di Torino
Corso Dogliotti 14, 10126 Turin, Italy
Email: davidegiuseppe.ribaldone@unito.it

Kind regards,

Davide Giuseppe Ribaldone

Davide Giuseppe Ribaldone